SS‑31 (Elamipretide) | What the Mitochondrial Studies Measured SS-31 takes peptide science inside the mitochondrion, where a membrane's architecture helps cells produce energy. Also called elamipretide, this four-amino-acid molecule belongs to the Szeto-Schiller family. Hazel Szeto at Cornell in New York and Peter Schiller in Montreal helped develop the peptides. A landmark paper appeared in 2004: more than twenty years of published research. Its partner is cardiolipin, a lipid in the inner mitochondrial membrane. This membrane folds into cristae, supporting electron transport and production of ATP, the cell's energy currency. Laboratory studies found that SS-31 interacts with cardiolipin and supports mitochondrial energy processes. A small randomized study in older adults reported improved muscle mitochondrial energy production after one infusion. This did not establish longer life or lasting performance benefits. In September 2025, the FDA granted accelerated approval to Forzinity, an elamipretide medicine, to improve muscle strength in adults and children with Barth syndrome weighing at least thirty kilograms. This rare genetic condition affects mitochondrial function. Approval drew on knee-extensor strength improvements during an open-label extension. The randomized trial did not show superiority on its walking and fatigue primary endpoints. A confirmatory trial is required. Risks include injection-site reactions and serious allergic reactions. This specific approval does not cover general anti-aging use or every product sold as SS-31. From molecular design to a rare-disease medicine, its story shows why mitochondrial membranes matter. World Peptide Foundation. Peptides in 2. Every experience matters.